ALX Oncology Holdings Inc. has outlined a mid-2027 topline readout from approximately 80 patients in the Phase 2 ASPEN-09-Breast trial of evorpacept in combination with trastuzumab and chemotherapy for HER2-positive metastatic breast cancer, after exploratory Phase 1b/2 data with evorpacept and zanidatamab showed a 22.1-month median progression-free survival in a small CD47-high cohort. The update gives the U.S.-based biotechnology firm a clearer biomarker-driven path for evorpacept, but also raises the bar for proving that CD47 expression can reliably identify patients most likely to benefit after prior HER2-directed therapy.
Why ALX Oncology’s CD47-high breast cancer signal changes the evorpacept debate
The most important feature of ALX Oncology’s latest update is not simply that evorpacept generated activity in heavily pretreated HER2-positive metastatic breast cancer. The more commercially relevant point is that the activity appeared concentrated in patients whose tumors had higher CD47 expression, suggesting that ALX Oncology may be moving away from a broad immuno-oncology bet and toward a more selective development model.
That distinction matters because CD47 has been one of oncology’s more difficult targets. The scientific premise remains attractive: blocking CD47 is intended to remove a “don’t eat me” signal used by cancer cells to evade macrophage-mediated immune clearance. However, the broader CD47 field has struggled to translate biological logic into consistent late-stage clinical success. For ALX Oncology, the emerging question is whether evorpacept can avoid the trap that has weakened parts of the CD47 class by being deployed in a better-defined patient population, rather than being pushed as a broad checkpoint-style add-on.
The exploratory breast cancer dataset gives ALX Oncology a more focused story. Across 24 patients in the Phase 1b/2 trial of evorpacept plus zanidatamab, the confirmed objective response rate was 33 percent and median progression-free survival was 3.6 months. Among 10 patients with centrally confirmed HER2-positive disease, the confirmed objective response rate rose to 60 percent, with median progression-free survival of 8.3 months. The sharpest signal came in five patients with centrally confirmed HER2-positive disease and high CD47 expression, all of whom responded, including one complete response and four partial responses, with median duration of response of 20.2 months and median progression-free survival of 22.1 months. In the lower CD47 expression group, the confirmed objective response rate was 25 percent and median progression-free survival was 3.4 months.
The risk is obvious, and it is the kind of risk clinicians and investors will not ignore. Five responding patients can generate a compelling hypothesis, but they cannot settle a development question. Small subgroup data are especially vulnerable to baseline imbalances, assay variability, patient-selection effects, and retrospective optimism. The upcoming ASPEN-09-Breast readout therefore becomes less of a routine Phase 2 update and more of a stress test for whether CD47 expression can function as a practical predictive biomarker.
How ASPEN-09 could clarify the post-trastuzumab deruxtecan treatment gap
The clinical setting is important because HER2-positive metastatic breast cancer has changed substantially with the rise of antibody-drug conjugates, particularly trastuzumab deruxtecan. Patients who progress after modern HER2-directed regimens remain a difficult population for drug developers, because they may have already received multiple HER2-targeted therapies and may have tumors that are biologically more resistant.
ALX Oncology’s earlier evorpacept plus zanidatamab study included heavily pretreated patients, all of whom had received prior trastuzumab deruxtecan, with a median of five prior HER2-targeted therapies. That makes the CD47-high signal clinically interesting because durable responses in this setting are harder to dismiss as routine HER2 sensitivity. It also makes the next trial strategically important because payers, regulators, and clinicians will want to know whether the apparent benefit survives in a larger and more controlled treatment context.
ASPEN-09-Breast is designed to evaluate evorpacept with trastuzumab and physician’s choice of chemotherapy in patients with HER2-positive breast cancer previously treated with trastuzumab deruxtecan. That design could help ALX Oncology answer a more commercially meaningful question than the Phase 1b/2 dataset could answer alone: whether evorpacept can improve outcomes when layered onto a familiar HER2 backbone rather than paired with zanidatamab, another active HER2-directed antibody.
The unresolved issue is how cleanly the mid-2027 readout will separate the effect of evorpacept from the effect of background therapy and patient selection. If ASPEN-09 shows stronger performance in CD47-high patients, ALX Oncology could strengthen the argument for a biomarker-enriched path forward. If the broader 80-patient dataset looks uneven, or if the CD47-high subset remains too small for confident interpretation, the update may create more questions than answers.
Why biomarker execution may matter as much as clinical response
The CD47-high finding gives ALX Oncology a potentially sharper development thesis, but it also creates an operational burden. A biomarker strategy only becomes clinically useful if the test is reproducible, the cutoff is credible, and the eligible patient population is large enough to support development and eventual commercialization.
In the exploratory analysis, high CD47 expression was defined by total membrane staining above 20 percent. That threshold may be useful for hypothesis generation, but Phase 2 and later-stage development will need to show that the cutoff is not arbitrary and that it can consistently identify likely responders across sites, tissue samples, and real-world pathology workflows. This is especially relevant in metastatic breast cancer, where archival tissue, evolving tumor biology, and prior treatment exposure can complicate biomarker interpretation.
Industry observers tracking oncology drug development will likely watch whether ASPEN-09 supports CD47 expression as a binary enrichment tool or whether response exists across a continuum. A clean high-versus-low split would simplify future trial design and make regulatory discussions more straightforward. A blurrier signal would not necessarily kill evorpacept, but it would make the program harder to position against established HER2 sequencing strategies and competing targeted approaches.
The adoption question is also practical. If evorpacept ultimately requires CD47 testing, ALX Oncology would need to show that the diagnostic workflow is not a barrier. Clinicians may accept another biomarker if the clinical benefit is large and durable. They will be less tolerant if the benefit is modest, the assay is cumbersome, or the treatment pathway remains unclear after trastuzumab deruxtecan.
What the ALX Oncology update means for investor sentiment around ALXO stock
ALX Oncology’s clinical update comes at a time when investors are treating small-cap biotechnology stories with selective enthusiasm rather than blanket risk appetite. ALXO stock recently traded around $2.08, with a market capitalization of about $217.5 million, reflecting both renewed interest in the clinical signal and continuing skepticism about the distance between exploratory response data and regulatory-grade evidence.
The share-price reaction matters less than the new investor framework. ALX Oncology is no longer asking the market to believe only in CD47 biology. It is asking investors to believe in a more specific sequence: CD47-high expression may identify responsive HER2-positive tumors, evorpacept may amplify HER2-directed therapy, ASPEN-09 may validate that approach in a larger post-trastuzumab deruxtecan population, and a future development program may be designed around that biomarker logic.
That is a more disciplined story, but it is still a high-risk story. ALX Oncology reported $169.1 million in cash, cash equivalents, and investments as of March 31, 2026, and said this was expected to fund planned operations through the first half of 2028. The biotechnology firm also reduced first-quarter research and development expenses to $13.6 million from $23.9 million a year earlier, partly reflecting workforce reductions and a narrower clinical development strategy.
That financial runway gives ALX Oncology time to reach key milestones, including ASPEN-09 topline data in mid-2027 and Phase 1 ALX2004 safety data in the second half of 2026. However, it also concentrates investor attention on execution. A stronger balance sheet does not remove clinical risk. It simply gives ALX Oncology enough room to prove whether its narrower pipeline strategy can produce data strong enough to justify further investment.
What clinicians, regulators, and industry watchers will look for next
The next major question is whether ASPEN-09 can reproduce the directional signal seen in the exploratory evorpacept plus zanidatamab analysis while generating enough confidence around durability, safety, and biomarker selection. In oncology, a response signal can attract attention, but durability and patient selection often decide whether a program becomes clinically relevant.
Clinicians will likely focus on whether evorpacept delivers benefit after trastuzumab deruxtecan in a way that feels meaningfully different from available sequencing options. Regulators will likely examine whether CD47 expression is analytically and clinically validated enough to support enrichment, stratification, or future labeling discussions. Investors will likely focus on whether the 80-patient Phase 2 readout is strong enough to support a larger, more expensive registration-oriented strategy.
Safety also remains important. CD47 biology has class-level complexity because CD47 is expressed on normal cells as well as tumor cells. Evorpacept has been designed to reduce some of the liabilities associated with earlier CD47 approaches, but the real test is whether combination regimens can maintain tolerability while adding enough efficacy to justify use in a crowded HER2-positive treatment landscape.
The mid-2027 ASPEN-09 readout therefore sits at the center of the ALX Oncology story. If the data confirm that CD47-high tumors derive a disproportionate and durable benefit from evorpacept-based therapy, ALX Oncology could reposition evorpacept as a biomarker-guided immuno-oncology asset rather than a broad CD47 experiment. If the signal fades in a larger dataset, the update may reinforce the old skepticism around CD47 as a difficult target with tantalizing biology but uncertain clinical translation.
For now, the latest data give ALX Oncology something more valuable than a headline response rate. They give the biotechnology firm a testable thesis. In biotech, that is useful. In Phase 2 oncology, it is also where the pressure really begins.
Why ALX Oncology’s ASPEN-09 readout may matter beyond one HER2 breast cancer study added by Pallavi Madhiraju on
View all posts by Pallavi Madhiraju →